CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,169 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02008357
NCT02008357Phase 3Completed
CompareCT.gov

Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)

Eli Lilly and Company·interventional·Posted Dec 11, 2013·Updated Dec 28, 2023

In Brief

A Phase 3 clinical trial evaluating Placebo and Solanezumab for Cognition Disorders. Completed, enrolled 1,169 participants across 68 sites in 4 countries.

Detailed Summary

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease \[AD\]).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCognition Disorders
CountriesAustralia, Canada, Japan, United States
CollaboratorsAlzheimer's Therapeutic Research Institute

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 11, 2013
Enrollment StartFeb 28, 2014
Primary CompletionDec 27, 2022
Study CompletionJun 8, 2023
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 12.6 years ago

Interventions

Placebodrug

Administered IV

Solanezumabdrug

Administered IV